Health activists and patients with spinal muscular atrophy (SMA) have refuted the Central government’s affidavit in the Kerala High Court and demanded urgent action to reduce the cost of ...
Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...
Zacks.com on MSN6d
FDA & EMA Accept Biogen's Filings for Higher Dose SMA DrugBiogen BIIB announced that the FDA and EMA have accepted its regulatory filings seeking label expansion for a higher dose of ...
More research is needed to confirm gray matter, the darker tissue found in the brain and spinal cord, “as a potential disease ...
for patients of spinal muscular atrophy (SMA) costs Rs 72 lakhs a year in India. A case in this regard has been going on in the Kerala High Court for a while now. On 22nd the Central government ...
Regulators in the U.S. and the European Union agreed to review Biogen’s applications for approval of a higher dose Spinraza ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback